Loading clinical trials...
Loading clinical trials...
Interaction Between Air Pollution, Pollens and Allergic Rhinitis in the Aix-Marseille-Provence Metropolis
Seasonal allergic rhinitis has multiple consequences: sleep disturbances, fatigue, depressed mood, impaired quality of life and productivity, and co-morbid conditions such as asthma, which affects one third of AR patients. In Europe, more than 150 million people suffer from allergic rhinitis and more than 25 million suffer from asthma. About 30% have uncontrolled rhinitis during exposure to allergens. The impact of allergic diseases on work productivity is estimated to be between 30 and 50 billion € per year in the EU. Studies show that pollution can play a role in the amplification of the response to inhaled pollen allergens by inducing morphological and functional modifications of nasal and bronchial epithelia, but also by inducing structural modifications of allergenic molecules. However, although data show that the symptoms of AR are aggravated by exposure to air pollution, this effect is not observed for all pollens. The study area is very exposed to pollens (with a significant presence of cypress pollen) and air pollution, and presents a prevalence of asthma of 17% while the national average is about 7%. The aim of this study is to establish, if they exist, links between pollens of various species, air pollution and symptoms of allergic rhinitis. The knowledge of these links will allow public authorities to set up prevention actions, and patients to better manage their allergic rhinitis on a daily basis.
For this study, the investigators will collect real life data from volunteer citizens via the MASK-air® mobile application, and exposure data to air pollutants and pollens from their partners. The data will be collected over one year in order to cover all pollen seasons. A communication of the project will be deployed to the citizens in the study area. The recruitment of participants will be done via an internet page accessible to all and presenting the MISTRAL study. Interested citizens can then access the electronic consent platform. After signing the participation agreement, they will receive a link to download the MASK-air® mobile application (freely available via the Android and Apple stores) and a personal study code, which will allow them to install the application on their smartphone. Participants will report their symptoms on the MASK-air app on a daily basis. Entry will only take 1 minute/day. This real-life data will be correlated with air pollution and pollen exposure data. In anticipation of the prevention actions that will be deployed by the public authorities following this study, an analysis of the expectations and needs of the citizens will be carried out among a part of the participants in the form of 4 questionnaires.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Https://Clin.Edop.Fr/Etude-Mistral
Montpellier, France
Start Date
June 22, 2021
Primary Completion Date
June 30, 2022
Completion Date
June 30, 2022
Last Updated
October 19, 2023
1,215
ACTUAL participants
Exposure to pollen and air pollution
OTHER
Lead Sponsor
MASK-air SAS
NCT05186025
NCT06085963
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions